Skip to main content
. Author manuscript; available in PMC: 2009 Jul 1.
Published in final edited form as: Semin Hematol. 2008 Jul;45(3 Suppl 2):S2–S6. doi: 10.1053/j.seminhematol.2008.07.003

Table 1.

Compounds studied in rituximab-refractory population

Compound Study N CR/CRu (%) ORR (%)
Bendamustine Friedberg et al. J Clin Oncol 2008 74 34 77
90Y ibritumomab Witzig et al. J Clin Oncol 2002 54 15 74
131I tositumomab Horning et al. J Clin Oncol 2005 40 38 65

CR, complete response; CRu, unconfirmed complete response; ORR, overall response rate